Water-free cyclosporine was more effective in improving total corneal fluorescein staining (tCFS) and symptoms of dry eye disease (DED), but did not improve dryness scores, a new Chinese study has found.
A randomised, multicentre, double-blind, phase 3 clinical trial of water-free ciclosporin ophthalmic solution, 0.1% (SHR8028, CyclASol, Novaliq) was conducted between 2021–2022 across 12 hospitals in China.
The study found the solution exhibited superiority over vehicle in improving total tCFS), but not dryness score, at day 29 among patients with DED.
“Water-free ciclosporin ophthalmic solution showed superiority over vehicle at 29 days in improving total corneal fluorescein staining. Between-group difference in dryness score (visual analog scale (VAS)) at day 29 was not found, and assessment of central CFS, total conjunctival staining, and blurred vision also favoured water-free cyclosporine over vehicle,” the researchers said.
The study was published in JAMA Ophthalmology.1
water-free ciclosporin ophthalmic solution showed superiority over vehicle at 29 days in improving total corneal fluorescein staining
Ciclosporin is an effective immunosuppressant widely used for treating moderate to severe DED. CyclASol is availabile in the United States under the brand name Vevye. It is under evaluation by the Therapeutic Goods Administration in Australia.
Reference
- Peng, R., Jie, Y., Long, Q., et al., Water-free cyclosporine ophthalmic solution vs vehicle for dry eye disease: A randomized clinical trial. JAMA Ophthalmol. Published online March 07, 2024. DOI:10.1001/jamaophthalmol.2024.0101.